^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastric Adenocarcinoma

    Related cancers:
    14h
    A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (clinicaltrials.gov)
    P1, N=42, Terminated, Prelude Therapeutics | Trial completion date: Apr 2027 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Jan 2026; Sponsor decision
    Trial completion date • Trial termination • Trial primary completion date • First-in-human
    1d
    Case Report: Pathologic complete response to PRaG therapy in an elderly patient with refractory metastatic gastric cancer. (PubMed, Front Oncol)
    The tumor demonstrated significant shrinkage following PRaG treatment and ultimately achieved pathologic complete response (pCR), with no serious adverse events aside from mild abdominal pain (NRS score 2). This case suggests that PRaG therapy may represent a promising therapeutic approach for patients with metastatic HAS.
    Journal
    |
    CSF2 (Colony stimulating factor 2)
    2d
    Copy-number amplification drives IFI30 overexpression and coordinated immune activation, identifying a novel diagnostic and therapeutic target in gastric adenocarcinoma. (PubMed, Sci Rep)
    Its high expression integrates tumor-intrinsic programs (cell cycle, EMT, hypoxia) with tumor-extrinsic immune activation, predicts differential drug sensitivities, and outperforms established biomarkers in forecasting response to immune-checkpoint blockade-particularly in MSI-high disease. These findings nominate IFI30 as a promising diagnostic marker and therapeutic target.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IRF1 (Interferon Regulatory Factor 1) • SPI1 (Spi-1 Proto-Oncogene) • FOXP3 (Forkhead Box P3)
    |
    MSI-H/dMMR
    2d
    Association of clinicopathological characteristics and baseline peripheral blood lymphocyte subsets with efficacy of first-line immunotherapy in advanced gastric cancer. (PubMed, Discov Oncol)
    Clinicopathological characteristics and baseline peripheral lymphocyte subsets were significantly associated with efficacy of first-line chemotherapy combined with ICIs in pMMR HER2-negative advanced G/GEJC, highlighting the potential utility of integrating these accessible parameters for efficacy prediction.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    2d
    ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, University of California, Irvine | Initiation date: Nov 2025 --> Apr 2026
    Trial initiation date • Checkpoint inhibition • IO biomarker
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    2d
    Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=168, Recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    paclitaxel • Cyramza (ramucirumab) • Ziihera (zanidatamab-hrii)
    3d
    Real-World Retrospective Study: Efficacy Evaluation of Different Chemotherapy Regimens Alone or in Combination with Immunotherapy in Patients with Advanced Gastric Cancer (ChiCTR2600117542)
    P=N/A, N=500, Not yet recruiting, Huashan Hospital Fudan University; Huashan Hospital Fudan University
    New trial
    3d
    The efficacy and safety of circular stapler esophagogastric/esophagojejunostomy under traction laparoscopy (ChiCTR2600116911)
    P=N/A, N=63, Completed, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New trial
    3d
    A retrospective and observational study to construct a prediction model for liver metastasis and prognosis of AFP-positive gastric cancer using common clinical, imaging, and pathological data (ChiCTR2500115549)
    P=N/A, N=600, Not yet recruiting, The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine
    New trial
    |
    AFP (Alpha-fetoprotein)
    3d
    A Study on the Short-Term Clinical Outcomes of Reduced-Port Robotic versus Conventional Laparoscopic Radical Gastrectomy for Gastric Cancer (ChiCTR2500115493)
    P=N/A, N=80, Not yet recruiting, The Second Hospital of Lanzhou University; The Second Hospital of Lanzhou University
    New trial
    3d
    An application study of a CT-based deep learning model for automatic segmentation and predication of lymph node metastasis in gastric cancer (ChiCTR2500115203)
    P=N/A, N=0, Not yet recruiting, THE FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY; THE FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY
    New trial
    3d
    Non-Invasive Diagnosis of Gastric Cancer Based on Exhaled Breath Analysis and Machine Learning (ChiCTR2500115028)
    P=N/A, N=1000, Not yet recruiting, Chinese PLA General Hospital; Chinese PLA General Hospital
    New trial